Trial Profile
An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors GSK
- 30 Sep 2014 New trial record